Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Rascol

Showing results (1-10 of 354) with videos related to

Pageof 36
Sort By:
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa in Parkinson's diseaseOlivier Rascol
Neurology|October 12, 2005
Assessing the risk of a necessary harm: placebo surgery in Parkinson diseaseOlivier Rascol
Neurology|February 18, 2009
"Disease-modification" trials in Parkinson disease: target populations, endpoints and study designOlivier Rascol
Neurology|July 21, 2005
Transdermal delivery of dopaminergic agentsOlivier Rascol
Nature Reviews. Neurology|August 20, 2014
Parkinson disease: Can a new trial end controversy over when to use levodopa?Olivier Rascol
The Lancet. Neurology|January 22, 2019
CVT-301 for Parkinson's disease: dose and effect size issuesOlivier Rascol
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Physical exercise in Parkinson disease: moving toward more robust evidence?Olivier Rascol
The Lancet. Neurology|December 24, 2013
Jejunal levodopa infusion in Parkinson's diseaseOlivier Rascol
Movement Disorders Clinical Practice|October 27, 2018
Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's DiseaseOlivier Rascol
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2006
Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet needOlivier Rascol
Pageof 36

Showing results (1-10 of 354) with videos related to

Sort By:
Pageof 36
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa in Parkinson's diseaseOlivier Rascol
Neurology|October 12, 2005
Assessing the risk of a necessary harm: placebo surgery in Parkinson diseaseOlivier Rascol
Neurology|February 18, 2009
"Disease-modification" trials in Parkinson disease: target populations, endpoints and study designOlivier Rascol
Neurology|July 21, 2005
Transdermal delivery of dopaminergic agentsOlivier Rascol
Nature Reviews. Neurology|August 20, 2014
Parkinson disease: Can a new trial end controversy over when to use levodopa?Olivier Rascol
The Lancet. Neurology|January 22, 2019
CVT-301 for Parkinson's disease: dose and effect size issuesOlivier Rascol
Movement Disorders : Official Journal of the Movement Disorder Society|April 17, 2013
Physical exercise in Parkinson disease: moving toward more robust evidence?Olivier Rascol
The Lancet. Neurology|December 24, 2013
Jejunal levodopa infusion in Parkinson's diseaseOlivier Rascol
Movement Disorders Clinical Practice|October 27, 2018
Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's DiseaseOlivier Rascol
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2006
Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet needOlivier Rascol
Pageof 36